China SXT Pharmaceuticals (SXTC) Stock Analysis & Winston Score
China SXT Pharmaceuticals makes traditional Chinese medicine (TCM) products and sells them in China. Its core products include concentrated TCM granules, which are processed herbal medicines that dissolve in water and are easier to use than raw herbs. Its main customers are hospitals, clinics, and pharmacies across China. The company earns money by selling its TCM products directly to healthcare distributors and medical institutions. It operates almost entirely within China and is a small-cap company with a market cap near zero, reflecting serious financial stress — its operating margin is deeply negative, meaning it spends far more than it earns. The biggest risk facing the business is its ongoing inability to turn a profit, and it will need to significantly cut costs or grow revenue to remain a viable company.
Winston Score: 26/100 — Below Average
Below-average fundamentals — multiple weak pillars.
- Quality: Mixed (8/30)
- Growth: Weak (2/20)
- Cash Flow: Weak (0/10)
- Stability: Good (5/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $2.45
Market Cap: $2M
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Exchange: NASDAQ

